Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
about
Proliferative and non-proliferative lesions of the rat and mouse soft tissue, skeletal muscle and mesothelium.Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma AgonistsDevelopment of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities.Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.Mechanistic Pathways in Amide Activation: Flexible Synthesis of Oxazoles and Imidazoles.Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat.PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.Early toxicology signal generation in the mouse.Direct N-alkylation of unprotected amino acids with alcohols.
P2860
Q33880079-E87AB9DB-DCE2-495A-94E4-3CE70770FA9FQ36073447-BAD6D66B-D64D-4A59-B52C-E837E0165A1AQ37077098-BD36B057-E746-4CB5-90DE-F820E032AD81Q37137719-B42232F5-CEA6-4FFD-AB7F-353B48FC4930Q38061184-B088231C-23BC-49C4-B134-EE0DB67A3D8EQ39771912-A408CBAB-9A38-4174-8908-2412F37E7069Q41110549-F58D72FC-6506-4993-9705-1A1F7F5EFBDFQ42728391-8C63CD31-BFEA-4156-855B-694ECF976548Q43222810-09F63C95-5650-459D-B4AE-E175D3A0E0FFQ43287595-F0F578AB-2011-4B97-A5F9-ADACC2BCD344Q46170974-4C4EB73C-109E-4838-AADB-9FF6EA4350C0Q47094747-A4BDA113-0513-43E9-9A6D-1ECB010BB197
P2860
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@ast
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@en
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@nl
type
label
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@ast
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@en
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@nl
prefLabel
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@ast
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@en
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@nl
P2093
P2860
P356
P1476
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
@en
P2093
Beth E Schilling
Crystal R Waites
Mark A Dominick
Thomas P Sanderson
P2860
P304
P356
10.1093/TOXSCI/KFM193
P577
2007-08-04T00:00:00Z